New first-in-human study initiations feature yet more in vivo Car assets.
ApexOnco Front Page
Recent articles
Intismeran autogene’s Interpath-001 trial reads out this year.
An in vivo Car-T produced a 100% response rate – in three patients.
Rival BTK degraders face off, as do bispecific Cars and T-cell engagers.
Data will be presented on Kura’s Komzifti and Syndax’s Revuforj in first-line AML.
Arcellx and AstraZeneca take centre stage.
Five years after settling, GSK is again accused of breaching the Jemperli deal.
Meanwhile, Zai Lab faces delays in its pivotal DLL3 trial.
